NO20065201L - terapeutiske peptider - Google Patents

terapeutiske peptider

Info

Publication number
NO20065201L
NO20065201L NO20065201A NO20065201A NO20065201L NO 20065201 L NO20065201 L NO 20065201L NO 20065201 A NO20065201 A NO 20065201A NO 20065201 A NO20065201 A NO 20065201A NO 20065201 L NO20065201 L NO 20065201L
Authority
NO
Norway
Prior art keywords
ligand
present
provides
therapeutic peptides
product
Prior art date
Application number
NO20065201A
Other languages
English (en)
Norwegian (no)
Inventor
Mumtaz Virji
Original Assignee
Univ Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0408390A external-priority patent/GB0408390D0/en
Priority claimed from GB0419594A external-priority patent/GB0419594D0/en
Application filed by Univ Bristol filed Critical Univ Bristol
Publication of NO20065201L publication Critical patent/NO20065201L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20065201A 2004-04-15 2006-11-13 terapeutiske peptider NO20065201L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0408390A GB0408390D0 (en) 2004-04-15 2004-04-15 Therapeutic peptides
GB0419594A GB0419594D0 (en) 2004-09-03 2004-09-03 Therapeutic peptides
PCT/GB2005/001465 WO2005099337A2 (fr) 2004-04-15 2005-04-15 Peptides therapeutiques

Publications (1)

Publication Number Publication Date
NO20065201L true NO20065201L (no) 2006-11-13

Family

ID=35033424

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065201A NO20065201L (no) 2004-04-15 2006-11-13 terapeutiske peptider

Country Status (11)

Country Link
EP (2) EP1735446A2 (fr)
JP (2) JP4960219B2 (fr)
KR (1) KR20070001274A (fr)
AU (1) AU2005232437B2 (fr)
BR (1) BRPI0509936A (fr)
CA (1) CA2563332A1 (fr)
IL (1) IL178517A0 (fr)
MX (1) MXPA06011501A (fr)
NO (1) NO20065201L (fr)
NZ (1) NZ551204A (fr)
WO (1) WO2005099337A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029271A2 (fr) 2006-02-27 2008-03-13 Gal Markel Agents antibactériens à base de ceacam
EP2042187A1 (fr) * 2007-09-27 2009-04-01 Charité-Universitätsmedizin Berlin (Charité) Utilisation de CEACAM8 soluble pour le diagnostic, le traitement ou la surveillance de maladie et procédé pour cribler les composants qui préviennent l'apoptose
EP3087099A4 (fr) * 2013-12-23 2017-07-19 Oncomed Pharmaceuticals, Inc. Immunothérapie à l'aide d'agents liants
GB201803692D0 (en) * 2018-03-08 2018-04-25 Glaxosmithkline Biologicals Sa Immunogenic composition
US20230407291A1 (en) * 2020-11-17 2023-12-21 Yale University Targeting host-bacteria interactions for the treatment of microbiota-mediated diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0948625B1 (fr) * 1996-12-20 2011-01-26 The Board Of Regents, The University Of Texas System Antigenes uspa1 et uspa2 de moraxella catarrhalis
GB0222764D0 (en) * 2002-10-02 2002-11-06 Univ Bristol Therapeutic peptide

Also Published As

Publication number Publication date
EP2468863A1 (fr) 2012-06-27
EP1735446A2 (fr) 2006-12-27
WO2005099337A2 (fr) 2005-10-27
JP4960219B2 (ja) 2012-06-27
WO2005099337A3 (fr) 2006-08-10
CA2563332A1 (fr) 2005-10-27
IL178517A0 (en) 2007-02-11
MXPA06011501A (es) 2007-01-26
AU2005232437B2 (en) 2011-10-06
KR20070001274A (ko) 2007-01-03
JP2012097099A (ja) 2012-05-24
BRPI0509936A (pt) 2007-09-25
JP2007532618A (ja) 2007-11-15
AU2005232437A1 (en) 2005-10-27
NZ551204A (en) 2010-03-26

Similar Documents

Publication Publication Date Title
Angeletti et al. Understanding and manipulating viral immunity: antibody immunodominance enters center stage
Davies et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice
Choi et al. Chimeric hemagglutinin-based influenza virus vaccines induce protective stalk-specific humoral immunity and cellular responses in mice
BR112022018088A2 (pt) Novos anticorpos anti-lilrb4 e produtos derivados
Maeda et al. Adjuvant-mediated epitope specificity and enhanced neutralizing activity of antibodies targeting dengue virus envelope protein
BR112019018307A2 (pt) Plataforma para identificação de peptídeos imunogênicos baseada em população
BR112019021991A2 (pt) Proteínas de ligação ao antígeno trem2 e seus usos
DK2918598T3 (en) Brachyury polypeptides and methods of use
Scholzen et al. Promiscuous Coxiella burnetii CD4 epitope clusters associated with human recall responses are candidates for a novel T-cell targeted multi-epitope Q fever vaccine
CN102307593A (zh) 轴突变性的调节
US20090062512A1 (en) Comparative ligand mapping from MHC class I positive cells
Yodsheewan et al. Human monoclonal ScFv specific to NS1 protein inhibits replication of influenza viruses across types and subtypes
NO20065201L (no) terapeutiske peptider
BR112022024339A2 (pt) Anticorpos anti cd200r1 e métodos de uso dos mesmos
EP1994406A1 (fr) Procédés d'identification d'épitopes de lymphocytes t associés à une compromission de la transformation de peptides et applications des épitopes identifiés
Bian et al. Characterization of immunogenicity of malignant cells with stemness in intrahepatic cholangiocarcinoma by single‐cell RNA sequencing
Kuehnle et al. CRISPR screens identify novel regulators of cFLIP dependency and ligand-independent, TRAIL-R1-mediated cell death
WO2011160174A1 (fr) Traitement de maladies prolifératives
NO20052108L (no) Terapeutiske peptider.
Maciel Jr et al. Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB/c (H2d) mice model
WO2022131832A1 (fr) Nouvelle composition vaccinale pour la prévention et le traitement du coronavirus
US11690902B2 (en) Coxiella burnetii epitopes for T cell-targeted Q fever vaccines
WO2015025165A1 (fr) Épitopes de lymphocytes t du virus de la peste porcine classique
Zhang et al. Elicitation of protective immune responses against influenza a viruses in elderly ferrets by adjuvanted recombinant universal influenza hemagglutinin vaccines
WO2006046134A3 (fr) Procede d'essai par le biais de peptides sensibles a la conformation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application